- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03276741
Oral Intake During Labor
April 22, 2020 updated by: Jeanette Anderson, David Grant U.S. Air Force Medical Center
Unrestricted Low Fat, Low Residue Oral Intake During Labor: A Randomized Controlled Study
A randomized clinical trial (RCT) to evaluate the impact of unrestricted low fat, low residue oral intake during labor on maternal and neonatal outcomes as well as maternal satisfaction.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This study is a quantitative, randomized experimental design study to determine the impact of unrestricted low fat, low residue oral intake during labor on the indicated outcome variables and patient satisfaction.
The comparison group will continue standard care of being allowed a clear liquid during active labor (≥6cm dilation), while the experimental group would be allowed to self-regulate oral intake with a low fat, low residue diet during active labor.
Study Type
Interventional
Enrollment (Actual)
126
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Travis Air Force Base, California, United States, 94535
- USAF David Grant Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Active Duty and Department of Defense (DoD) beneficiary Pregnant women 18 years of age and older
- 37 weeks gestation or greater at time of admission
- singleton fetus
- cephalic presentation
- who plan to labor/deliver at DGMC (military beneficiaries).
Exclusion Criteria:
- Morbid/severe obesity (pre-pregnancy BMI ≥40 kg/m2
- diabetes
- hypertension (to include pre-eclampsia or eclampsia)
- previous cesarean section
- uncontrolled gastroesophageal reflux disease (GERD) (symptomatic with medication)
- past history or current diagnosis of hyperemesis gravidarum
- food allergies to any items contained in the gastric/soft bland diet
- patients utilizing nitrous oxide for labor analgesia (should this treatment be available at DGMC)
- Difficult airway as defined by the anesthesia staff.
- Mallampati score 3 or 4
- Thyroid mental distance less than 7 cm or 3 finger breaths
- Mouth opening less than 3 finger breaths
- Short thick neck, Micrognathia
- Further indications as determined by the anesthesia provider doing the anesthesia preoperative assessment (pregnancy in and of itself will not be considered a disqualification due to airway changes during labor)" in order to define difficult airway per anesthesia.
- Under age 18
- Additional clinical risk factors as determined by the care provider
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
Routine care during labor (authorized clear liquid diet).
|
|
Active Comparator: Experimental Group
Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy.
This will be ordered in the electronic medical record (EMR) and is a standard "non-select meal," referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections.
|
Patients in the experimental group will have a gastric soft/bland diet available.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nausea
Time Frame: active labor (6cm or greater dilation) through delivery of the infant
|
# episodes
|
active labor (6cm or greater dilation) through delivery of the infant
|
Vomiting
Time Frame: active labor (6cm or greater dilation) through delivery of the infant
|
# episodes
|
active labor (6cm or greater dilation) through delivery of the infant
|
Duration of labor
Time Frame: active labor (6cm or greater dilation) through delivery of the infant
|
#hours/minutes
|
active labor (6cm or greater dilation) through delivery of the infant
|
Mode of delivery
Time Frame: at birth
|
cesarean section, operative vaginal delivery, spontaneous vaginal delivery
|
at birth
|
Aspiration
Time Frame: active labor (6cm or greater dilation) through delivery of the infant
|
# episodes
|
active labor (6cm or greater dilation) through delivery of the infant
|
Newborn APGAR Score
Time Frame: 5 min of life
|
< 7
|
5 min of life
|
Maternal Satisfaction
Time Frame: active labor (6cm or greater dilation) through delivery of the infant
|
open ended survey question
|
active labor (6cm or greater dilation) through delivery of the infant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jeanette M Anderson, MSN, David Grant Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 29, 2017
Primary Completion (Actual)
January 11, 2020
Study Completion (Actual)
January 11, 2020
Study Registration Dates
First Submitted
September 6, 2017
First Submitted That Met QC Criteria
September 7, 2017
First Posted (Actual)
September 8, 2017
Study Record Updates
Last Update Posted (Actual)
April 24, 2020
Last Update Submitted That Met QC Criteria
April 22, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FDG20170006H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Satisfaction
-
Shaukat Khanum Memorial Cancer Hospital & Research...Enrolling by invitationSatisfaction, Patient | SatisfactionPakistan
-
Nanne KleefstraCompletedPatient Satisfaction | Doctor Satisfaction | Duration of ConsultationNetherlands
-
Federal University of UberlandiaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Amparo...Completed
-
Halic UniversityCompletedWomen With Low Sexual Satisfaction | Partners of Women With Low Sexual SatisfactionTurkey
-
Harvard Pilgrim Health CareAmerican Heart Association; Harvard Vanguard Medical AssociatesCompleted
-
The Hospital for Sick ChildrenEnrolling by invitation
-
Ulrike WeberCompletedSatisfactionAustria
-
Brigham and Women's HospitalCompleted
-
Laval UniversityCompleted
-
Fu Jen Catholic UniversityNot yet recruitingSatisfaction, PersonalTaiwan
Clinical Trials on gastric soft/bland diet
-
Medical University of ViennaUnknownMorbid ObesityAustria
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedObesityUnited States
-
University of MinnesotaAmerican Diabetes AssociationCompletedType 2 Diabetes Mellitus | Insulin ResistanceUnited States
-
Uppsala UniversityAstraZenecaUnknownWeight Loss | Bariatric Surgery Candidate | Type2 Diabetes | Insulin Sensitivity | Metabolism and Nutrition Disorder | Metabolism Disorder, GlucoseSweden
-
The Hospital of VestfoldUniversity of Oslo; AstraZenecaActive, not recruiting
-
University Medical Center, KazakhstanCompleted
-
Azienda Ospedaliera Universitaria Integrata VeronaUniversita di VeronaCompleted
-
Enzychem Lifesciences CorporationCompletedChemotherapy-Induced NeutropeniaKorea, Republic of
-
Zhongda HospitalUnknown
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingObesity | Type 2 DiabetesUnited States